Assyro AI
FDA Orange Book · active-ingredient family

Prednisolone sodium phosphate; sulfacetamide sodium

Prednisolone sodium phosphate; sulfacetamide sodium: 1 brand, 3 generics; first approved Aug 26, 1988; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available — 3 ANDA applications approved.

Brands (NDA)
1
Generics (ANDA)
3
Listed patents
0
Presentations
4
Originator applications

Brand (NDA) products

NDA 0189881988
Approved strengths under this FDA application.
StrengthDosage formRouteStatusTE
EQ 0.23% PHOSPHATE;10% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION/DROPSOPHTHALMICDiscontinued
Abbreviated applications

Generic (ANDA) products (3)

ANDA 0745111996
Approved strengths under this FDA application.
StrengthDosage formRouteStatusTE
EQ 0.23% PHOSPHATE;10%SOLUTION/DROPSOPHTHALMICDiscontinued
Approved strengths under this FDA application.
StrengthDosage formRouteStatusTE
EQ 0.23% PHOSPHATE;10%SOLUTION/DROPSOPHTHALMICRx
Approved strengths under this FDA application.
StrengthDosage formRouteStatusTE
EQ 0.23% PHOSPHATE;10%SOLUTION/DROPSOPHTHALMICDiscontinued
Orange Book patent file

Listed patents

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

FDA approval span

Approval history

First approval
Aug 26, 1988
38 yr 5 mo ago
Most recent approval
Jul 30, 1996
30 yr 5 mo ago

Approvals span 1988–1996 across 4 FDA applications.

Brand (NDA) 125%
Generic (ANDA) 375%

Prednisolone sodium phosphate; sulfacetamide sodium — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.